###begin article-title 0
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages
###end article-title 0
###begin article-title 1
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-Cholesterol Connection Suggests a New Antiretroviral Strategy
###end article-title 1
###begin p 2
###xml 688 691 688 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 855 858 855 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 1140 1143 1140 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 69 72 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 265 268 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 325 328 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 424 429 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 516 521 <span type="species:ncbi:9606">human</span>
###xml 593 598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 664 670 <span type="species:ncbi:10090">murine</span>
###xml 819 822 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1123 1126 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1259 1262 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1356 1359 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1410 1413 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1423 1431 <span type="species:ncbi:9606">patients</span>
###xml 1753 1756 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1866 1869 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2022 2025 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2120 2123 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2178 2181 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2262 2265 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2275 2283 <span type="species:ncbi:9606">patients</span>
Several steps of HIV-1 replication critically depend on cholesterol. HIV infection is associated with profound changes in lipid and lipoprotein metabolism and an increased risk of coronary artery disease. Whereas numerous studies have investigated the role of anti-HIV drugs in lipodystrophy and dyslipidemia, the effects of HIV infection on cellular cholesterol metabolism remain uncharacterized. Here, we demonstrate that HIV-1 impairs ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol efflux from human macrophages, a condition previously shown to be highly atherogenic. In HIV-1-infected cells, this effect was mediated by Nef. Transfection of murine macrophages with Nef impaired cholesterol efflux from these cells. At least two mechanisms were found to be responsible for this phenomenon: first, HIV infection and transfection with Nef induced post-transcriptional down-regulation of ABCA1; and second, Nef caused redistribution of ABCA1 to the plasma membrane and inhibited internalization of apolipoprotein A-I. Binding of Nef to ABCA1 was required for down-regulation and redistribution of ABCA1. HIV-infected and Nef-transfected macrophages accumulated substantial amounts of lipids, thus resembling foam cells. The contribution of HIV-infected macrophages to the pathogenesis of atherosclerosis was supported by the presence of HIV-positive foam cells in atherosclerotic plaques of HIV-infected patients. Stimulation of cholesterol efflux from macrophages significantly reduced infectivity of the virions produced by these cells, and this effect correlated with a decreased amount of virion-associated cholesterol, suggesting that impairment of cholesterol efflux is essential to ensure proper cholesterol content in nascent HIV particles. These results reveal a previously unrecognized dysregulation of intracellular lipid metabolism in HIV-infected macrophages and identify Nef and ABCA1 as the key players responsible for this effect. Our findings have implications for pathogenesis of both HIV disease and atherosclerosis, because they reveal the role of cholesterol efflux impairment in HIV infectivity and suggest a possible mechanism by which HIV infection of macrophages may contribute to increased risk of atherosclerosis in HIV-infected patients.
###end p 2
###begin p 3
###xml 0 4 <span type="species:ncbi:11676?0.7906976744186046">HIV1</span>
###xml 182 185 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
HIV1-Nef impairs ABCA1-dependent cholesterol efflux from infected macrophages, promoting the transformation of virally infected macrophages into foam cells (a condition that may put HIV patients at risk for atherosclerosis).
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b001">1</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b002">2</xref>
###xml 499 500 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b003">3</xref>
###xml 501 502 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b004">4</xref>
###xml 871 872 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b005">5</xref>
###xml 158 161 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 179 182 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 358 363 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 668 671 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 751 756 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1012 1015 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophage cells and cholesterol play a central role in the pathogenesis of two diseases, AIDS and atherosclerosis. Macrophages are among the main targets of HIV in the body, and HIV assembly and budding, as well as infection of new target cells, all depend on plasma membrane cholesterol. Depletion of cellular cholesterol markedly and specifically reduces HIV-1 particle production [1,2], and cholesterol-sequestering drugs, such as beta-cyclodextrin, render the virus incompetent for cell entry [3,4]. Therefore, regulating cholesterol delivery to nascent virions would be highly beneficial for the virus. Some clues to potential mechanisms that may be employed by HIV to achieve this goal have been provided recently when it was demonstrated that HIV-1 accessory protein Nef binds cholesterol and may deliver it to the site of virion assembly at the plasma membrane [5]. However, little is known about the relation of this mechanism to major cellular cholesterol trafficking pathways and about the effect of HIV infection on lipid metabolism in the host cells.
###end p 5
###begin p 6
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b006">6</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b010">10</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b011">11</xref>
###xml 517 537 517 537 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Chlamydia pneumoniae</named-content>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b012">12</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b013">13</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b014">14</xref>
###xml 1299 1301 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b015">15</xref>
###xml 1419 1421 1419 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b016">16</xref>
###xml 1673 1675 1673 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b017">17</xref>
###xml 2080 2082 2080 2082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b018">18</xref>
###xml 2083 2085 2083 2085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b019">19</xref>
###xml 2175 2176 2175 2176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b007">7</xref>
###xml 2177 2178 2177 2178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b009">9</xref>
###xml 2179 2181 2179 2181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b010">10</xref>
###xml 2182 2184 2182 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b020">20</xref>
###xml 2185 2187 2185 2187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b022">22</xref>
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 517 537 <span type="species:ncbi:83558">Chlamydia pneumoniae</span>
###xml 1099 1102 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1112 1120 <span type="species:ncbi:9606">patients</span>
###xml 1838 1841 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1851 1859 <span type="species:ncbi:9606">patients</span>
###xml 1945 1948 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2002 2010 <span type="species:ncbi:9606">patients</span>
###xml 2054 2057 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2123 2126 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2239 2242 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Increased risk of atherosclerosis and coronary artery disease (CAD) is a recognized clinical problem in HIV-infected patients [6-10]. A key element of atherosclerotic plaque is formation of foam cells [11], the majority of which are macrophages overloaded with cholesterol. Foam cells undergo apoptosis, necrosis, and calcification, and cholesterol released from foam cells forms the lipid-rich core of the plaque. Interestingly, foam cells are less conducive than macrophages to growth of certain pathogens, such as Chlamydia pneumoniae [12], suggesting that they may contribute to antibacterial response of the organism. One of the main causes of foam cell formation and accumulation of cholesterol in the vessel wall may be dyslipidemia, especially high levels of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), as well as low levels of high-density lipoprotein (HDL) [13], and/or impairment of intracellular cholesterol metabolism. Dyslipidemia caused by antiretroviral drugs, in particular protease inhibitors (PIs) [14], is a known risk factor in pathogenesis of CAD in HIV-infected patients. One mechanism of PI treatment-dependent dyslipidemia is inhibition of degradation of proteins involved in metabolism of cholesterol and triglycerides, such as apolipoprotein B [15] or the adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element binding protein 1 [16]. In addition to causing dyslipidemia, PIs may contribute to initiation of atherosclerosis by affecting intracellular metabolism of cholesterol via up-regulation of the scavenger receptor CD36 and the subsequent accumulation of sterol in macrophages [17]. Therefore, PIs affect both extra- and intracellular pathways of cholesterol metabolism and are likely an important factor in pathogenesis of atherosclerosis in HIV-infected patients. However, a number of clinical reports found a correlation between heart disease and HIV viral load, and detected an increased risk of CAD in patients not treated with PIs or even in drug-naive HIV-infected individuals [18,19]. Recent results support the role of HIV infection as an independent risk factor of CAD [7,9,10,20-22], but the mechanisms of this atherogenic effect of HIV remain unknown.
###end p 6
###begin p 7
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b023">23</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b024">24</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b025">25</xref>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 540 545 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 698 701 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 736 739 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1066 1069 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1178 1181 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this report, we identify one such mechanism. We show that HIV, via its accessory protein Nef, affects normal function of ATP-binding cassette transporter A1 (ABCA1) and consequently impairs cholesterol efflux from infected macrophages. Previous studies demonstrated the key role of ABCA1 in reverse cholesterol transport and found that functional mutations in ABCA1 cause Tangier disease, which is characterized by severe HDL deficiency, accumulation of sterols in tissue macrophages, and accelerated atherosclerosis [23]. The effect of HIV-1 on ABCA1 is consistent with ABCA1 inhibition described for viral [24] and bacterial [25] infections; however, the mechanism of impairment is unique for HIV. As a result of ABCA1 inhibition, HIV-infected macrophages accumulate lipids and transform into foam cells, a step that may contribute to the increased risk of atherosclerotic plaque formation. Our results also suggest that cholesterol efflux impairment may be a mechanism that ensures access of nascent virions to intracellular cholesterol, which is critical for HIV infectivity. Therefore, pharmacological stimulation of cholesterol efflux may be considered as a novel anti-HIV therapeutic strategy.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 36 39 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Impairment of Cholesterol Efflux in HIV-Infected Macrophages
###end title 9
###begin p 10
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b026">26</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b027">27</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b028">28</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b029">29</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b030">30</xref>
###xml 588 596 588 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 932 940 932 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 1069 1070 1069 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1131 1132 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 383 389 <span type="species:ncbi:9606">humans</span>
###xml 487 492 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 689 694 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 795 800 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cholesterol efflux is a pathway for removing excessive cholesterol from cells to extracellular acceptors. It is the first step of reverse cholesterol transport, and it plays a key role in maintaining cell cholesterol homeostasis. Impairment of cholesterol efflux leads to accumulation of intracellular cholesterol [26] and development of atherosclerosis in animal models [27] and in humans [28,29]. Analysis of cholesterol efflux from monocyte-derived macrophages infected in vitro with HIV-1 ADA [30] demonstrated a substantial inhibition of apolipoprotein A-I (apoA-I)-specific efflux (Figure 1A). A similar effect was observed in macrophages infected with two primary macrophage-tropic HIV-1 strains, Yu-2 and 92US660, indicating that impairment of cholesterol efflux is a general feature of HIV-1 replication in macrophages (Figure 1A). The level of cholesterol efflux inhibition correlated with the level of virus replication (Figure 1A). Importantly, at the time of analysis (21 d after infection), 80%-90% of the cells infected with ADA and Yu-2 viruses were p24+ (only 20% of the cells infected with 92US660 strain were p24+ at that time), indicating that reverse transcription (RT) values in these infections reflected the amount of virus produced per cell and that cholesterol efflux impairment depended on the level of virus protein expression.
###end p 10
###begin title 11
Nef Is Critical for Cholesterol Efflux Impairment
###end title 11
###begin p 12
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b005">5</xref>
###xml 404 407 404 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b031">31</xref>
###xml 797 805 797 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 1061 1069 1057 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 187 190 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 348 353 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 508 534 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 558 563 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1121 1124 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Previous studies demonstrated that the HIV-1 protein Nef can directly bind cholesterol and suggested that in CD4+ T cells, Nef may be involved in transporting cholesterol to the sites of HIV assembly at the plasma membrane [5]. To test the role of Nef in the observed impairment of cholesterol efflux from macrophages, we infected macrophages with HIV-1 SF2 constructs carrying a mutated or a functional Nef gene. To ensure similar levels of infection, the constructs were pseudotyped by the glycoprotein of vesicular stomatitis virus (VSV-G), which targets HIV-1 entry to an endocytic pathway, thus eliminating the requirement for Nef in the early steps of infection [31]. Under these one-cycle replication conditions, both viruses infected about 40% of cells and produced similar levels of p24 (Figure 1B). Cholesterol efflux to apoA-I was substantially reduced in the culture infected with the Nef-positive virus (wild type [WT]), whereas in the culture infected with Nef-deficient virus (DeltaNef), it was similar to the level observed in uninfected cells (Figure 1B). This result indicates that Nef is necessary for HIV-mediated impairment of cholesterol efflux.
###end p 12
###begin p 13
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 444 452 444 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b005">5</xref>
###xml 707 715 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 780 788 780 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 91 97 <span type="species:ncbi:10090">murine</span>
###xml 868 871 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To determine whether Nef is sufficient for the observed effect, we transiently transfected murine macrophages RAW 264.7 with constructs expressing SF2-derived Nef and stimulated ABCA1 expression in these cells by liver X receptor (LXR) agonist TO-901317. Cholesterol efflux to apoA-I from Nef-transfected RAW 264.7 macrophages was significantly reduced (by more than 50%) compared to cells transfected with an empty vector (mock transfection) (Figure 1C). This result indicates that expression of Nef is sufficient to impair cholesterol efflux from macrophages. Interestingly, Nef mutant Nef.G2A, defective in myristoylation and membrane localization [5], was not effective in impairing cholesterol efflux (Figure 1C) despite levels of expression being similar to that of WT Nef (Figure 1D). Cholesterol efflux impairment in Nef-transfected RAW cells was less than in HIV-infected macrophages, likely due to differences between these cell types.
###end p 13
###begin title 14
Nef Specifically Targets ABCA1-Dependent Cholesterol Efflux
###end title 14
###begin p 15
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b032">32</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b033">33</xref>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 541 549 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b034">34</xref>
###xml 626 629 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 677 685 677 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 741 749 741 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 871 879 871 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 484 487 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Specific efflux of cholesterol from cells is mediated by the members of the family of ATP-binding cassette (ABC) transporters. The ABCA1 transporter is responsible for lipidation of lipid-poor apoA-I with cellular lipids [32], whereas ABCG1 controls efflux to mature HDL [33]. Our finding that Nef inhibits cholesterol efflux to apoA-I (Figure 1) suggests that ABCA1 may be the specific target of Nef. Consistent with this notion, cholesterol efflux to HDL (controlled by ABCG1) from HIV-infected macrophages was not significantly impaired (Figure 2A). Furthermore, phospholipid efflux, which is dependent on ABCA1 [34], from Nef-transfected RAW 264.7 macrophages was reduced (Figure 2B), similar to the effect of Nef on cholesterol efflux (Figure 1C). In addition, Nef did not affect cholesterol efflux from RAW 264.7 cells in which ABCA1 expression was not stimulated (Figure 2C) and consequently was very low.
###end p 15
###begin p 16
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b035">35</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b036">36</xref>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCA1</italic>
###xml 373 376 373 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 491 499 491 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 574 582 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 871 879 871 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 412 417 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The notion that ABCA1-mediated efflux is the target of Nef was further supported by experiments in HeLa cells, which do not express ABC transporters and have very low background cholesterol efflux to apoA-I [35]. Consistent with a previous report [36], transfection of HeLa cells with ABCA1 significantly enhanced cholesterol efflux to apoA-I, whereas co-transfection with Nef derived from SF2 or LAI strains of HIV-1 brought the efflux back to the level observed in mock-transfected cells (Figure 2D). Importantly, NefLAI, which was expressed to higher levels than NefSF2 (Figure 2D), was more effective also in cholesterol efflux impairment. A similar experiment testing the effect of Nef on ABCG1-directed cholesterol efflux showed stimulation of cholesterol efflux to HDL after transfection of HeLa cells with ABCG1, but did not reveal significant inhibition by Nef (Figure 2E). Therefore, we conclude that Nef specifically targets ABCA1-dependent cholesterol efflux.
###end p 16
###begin title 17
Nef Down-Regulates ABCA1
###end title 17
###begin p 18
###xml 171 174 171 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 324 332 324 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 496 504 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 804 812 804 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 889 897 889 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 1018 1026 1018 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 1049 1057 1049 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b037">37</xref>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 252 257 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 481 484 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1004 1007 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1401 1406 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Since ABCA1 appears to be the target of Nef, we tested ABCA1 abundance (by Western blotting) and transcription (by real-time RT-PCR) in HIV-infected human macrophages and Nef-transfected RAW 264.7 cells. Analysis of ABCA1 in macrophages at the peak of HIV-1 ADA replication showed a substantial decrease of ABCA1 abundance (Figure 3A). Importantly, abundance of two other proteins involved in cholesterol efflux to HDL, ABCG1 and scavenger receptor B1 (SR-B1), was not affected by HIV infection (Figure 3A), consistent with specific targeting of the ABCA1-dependent pathway by the virus. A similar phenomenon was observed in Nef-transfected RAW 264.7 macrophages, although the effect was less pronounced (approximately 50% reduction in ABCA1 abundance when assessed by densitometry of the Western blot) (Figure 3B). The Nef.G2A mutant, which was inactive in cholesterol efflux impairment (Figure 1C), was also inactive in depleting ABCA1. RT-PCR analysis revealed a significant increase of ABCA1 mRNA in HIV-infected (Figure 3C) or Nef-transfected (Figure 3D) cells, which likely reflects a compensatory response for the loss of ABCA1 [37]. This observation rules out a suppressive effect of Nef on ABCA1 transcription and suggests a post-transcriptional down-regulation of ABCA1 by Nef. Therefore, down-regulation of ABCA1 is one of the mechanisms responsible for impairment of cholesterol efflux by HIV-1.
###end p 18
###begin title 19
Nef Alters Intracellular Distribution of ABCA1
###end title 19
###begin p 20
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b036">36</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b038">38</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b039">39</xref>
###xml 515 523 515 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">4</xref>
###xml 555 563 555 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">4</xref>
###xml 736 738 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b036">36</xref>
###xml 907 915 899 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 974 982 966 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 1102 1103 1094 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1113 1121 1105 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 1260 1268 1252 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 1274 1275 1266 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">4</xref>
###xml 1361 1369 1353 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 197 200 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 659 664 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 819 824 <span type="species:ncbi:9606">human</span>
###xml 900 905 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 950 956 <span type="species:ncbi:10090">murine</span>
###xml 1046 1051 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1222 1228 <span type="species:ncbi:10090">murine</span>
Although down-regulation of ABCA1 alone would account for a substantial part of the inhibition of cholesterol efflux, we further found that intracellular distribution of ABCA1 was also affected by HIV infection. Recent reports established that ABCA1 resides both on the plasma membrane and in endocytic vesicles [36], and demonstrated the role of endosomal ABCA1 and trafficking of ABCA1 between endosomes and plasma membrane in the apoA-I-mediated efflux of cellular lipids from the endosomal compartment [38,39]. Figure 4A and 4B show p24 staining, and Figure 4C and 4D show ABCA1 distribution in human macrophages infected with DeltaNef and Nef-expressing HIV-1, respectively. Consistent with the findings of Neufeld and colleagues [36], ABCA1 was distributed evenly between the cytoplasm and the plasma membrane in human macrophages either uninfected (unpublished data) or infected with DeltaNef HIV-1 (Figure 4C), as well as in mock-transfected murine RAW 264.7 cells (Figure 4E). It appears that in macrophages infected with Nef-expressing HIV-1, ABCA1 was re-localized to the cell periphery (p24+ cells in Figure 4D). This re-localization of ABCA1 to the plasma membrane was even more pronounced in Nef-transfected murine macrophages RAW 264.7 (compare Figure 4E and 4F). No re-localization of ABCA1 was observed in macrophages transfected with Nef.G2A (Figure 4G). Therefore, Nef expression induces re-localization of ABCA1, which requires myristoylation of Nef.
###end p 20
###begin p 21
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b040">40</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b042">42</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b039">39</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b043">43</xref>
###xml 319 322 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 387 395 387 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 440 443 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 560 568 560 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 601 604 601 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
Previous studies demonstrated that apoA-I specifically binds to ABCA1 at the cell surface [40-42]. It was also suggested that trafficking of apoA-I to intracellular cholesterol pools correlates with trafficking of ABCA1 [39,43]. Consistent with re-localization of ABCA1 to the plasma membrane, the specific binding of [125I]apoA-I to Nef-transfected RAW 264.7 macrophages was increased (Figure 4H, left panel). However, internalization of [125I]apoA-I was almost completely blocked, supporting the model whereby Nef impairs intracellular trafficking of ABCA1 (Figure 4H, right panel). Degradation of [125I]apoA-I was negligible and was not affected by Nef (unpublished data).
###end p 21
###begin p 22
Therefore, Nef-dependent changes in intracellular distribution of ABCA1 may be another mechanism responsible for impairment of cholesterol efflux.
###end p 22
###begin title 23
Nef Interacts with ABCA1
###end title 23
###begin p 24
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b044">44</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b045">45</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b046">46</xref>
###xml 884 892 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 965 973 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
Nef has been shown to modulate expression of several trans-membrane proteins. In some cases (e.g., with CD4 or major histocompatibility complex [MHC] I) Nef down-regulates the protein, and in some (e.g., with invariant chain of MHC class II or with dendritic cell-specific ICAM-3-grabbing nonintegrin [DC-SIGN]), it up-regulates the protein's surface expression ([44] and references therein). Some of these effects, including down-regulation of CD4 [45] and MHC I [46], have been shown to depend on an interaction between Nef and the target protein. We therefore tested whether Nef interacts with ABCA1. HeLa cells were co-transfected with Nef or Nef.G2A and FLAG-tagged ABCA1, ABCA1 was immunoprecipitated using anti-FLAG antibody, and immunoprecipitates were analyzed for co-precipitation of Nef. This analysis revealed that Nef co-precipitated with ABCA1, whereas Nef.G2A did not (Figure 5A, upper panel) despite equally high expression of the two forms of Nef (Figure 5A lower panel). We conclude that Nef can interact with ABCA1, and this interaction requires myristoylation of Nef and correlates with the ability of Nef to impair cholesterol efflux. The Nef-specific signal observed in this experiment required high-level expression of participating proteins, likely due to the transitory nature of Nef interaction with ABCA1.
###end p 24
###begin p 25
###xml 209 217 209 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 280 288 280 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 373 381 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
Interaction between ABCA1 and Nef at the plasma membrane was supported by confocal microscopy, which demonstrated co-localization of Nef and ABCA1 in RAW 264.7 cells transfected with Nef.wt-expressing vector (Figure 5B). No co-localization was observed between ABCA1 and Nef.G2A (Figure 5B). This visual analysis was reinforced by an analytical quantification presented in Figure 5C. Indeed, both ABCA1 and the WT Nef proteins are found at the cell periphery, and their co-localization is indicated by overlapping green and blue peaks at either end of the graph. Moreover, both colors peak and valley in tandem, suggesting a correlation in subcellular localization of ABCA1 and WT Nef. No such correlation is observed in ABCA1 and Nef.G2A distribution. Taken together, these results suggest that interaction between ABCA1 and Nef occurs at the cell plasma membrane.
###end p 25
###begin p 26
Therefore, both re-localization and down-modulation of ABCA1 depend on its interaction with Nef, which in turn requires myristoylation and membrane localization of Nef.
###end p 26
###begin title 27
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-Infected Macrophages Transform into Foam Cells
###end title 27
###begin p 28
###xml 341 349 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 584 592 576 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 595 596 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">6</xref>
###xml 693 701 685 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 826 834 814 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 837 838 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">6</xref>
###xml 1048 1056 1036 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 1062 1063 1050 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">6</xref>
###xml 1218 1226 1206 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g006">Figure 6</xref>
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 210 215 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 748 753 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 811 816 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To determine whether impairment of cholesterol efflux by HIV-1 infection leads to cholesterol accumulation and foam cell formation, we loaded macrophages (uninfected or infected with Nef-expressing or DeltaNef HIV-1) with lipids by incubating with acetylated LDL (AcLDL) in the presence of apoA-I and stained cellular lipids with Oil Red O (Figure 6). This experiment revealed formation of typical lipid-rich cells in cultures infected with Nef-expressing HIV-1, whereas uninfected cells or macrophages infected with DeltaNef virus accumulated substantially less cholesterol (compare Figure 6A, 6B, and 6C). Analysis by transmission electron microscopy revealed more lipid vacuoles (arrows in Figure 6E) in macrophages infected with Nef-expressing HIV-1 than in uninfected cells or cells infected with DeltaNef HIV-1 (compare Figure 6D, 6E, and 6F). Cholesterol loading of RAW 264.7 macrophages transfected with Nef also led to accumulation of significantly larger amounts of lipids when compared to cells transfected with an empty vector (compare Figure 6H and 6I). In addition, Nef-transfected RAW 264.7 macrophages demonstrated accelerated cholesteryl ester synthesis, especially when cells were loaded with AcLDL (Figure 6G). Enhanced synthesis of cholesteryl esters is a sensitive indicator of accumulation of cholesterol inside the cells and a key element of foam cell formation.
###end p 28
###begin p 29
###xml 167 175 167 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g007">Figure 7</xref>
###xml 248 256 248 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g007">Figure 7</xref>
###xml 305 313 305 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g007">Figure 7</xref>
###xml 654 662 654 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g007">Figure 7</xref>
###xml 842 850 842 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 927 935 927 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g007">Figure 7</xref>
###xml 983 988 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Measurements of cholesterol mass confirmed substantially higher cholesteryl ester content in Nef-transfected RAW 264.7 macrophages compared to mock-transfected cells (Figure 7A); there was also more free cholesterol in the transfected macrophages (Figure 7B). Synthesis of triglycerides was not affected (Figure 7C), indicating that increased cholesteryl ester synthesis and content is a consequence of increased concentration of cholesterol rather than of fatty acids. The increased cholesterol content in Nef-transfected cells was not caused by differences in AcLDL uptake, as the latter was similar between Nef-transfected and mock-transfected cells (Figure 7D). To accommodate the increasing amounts of cholesteryl esters, cells would require an additional amount of phospholipids, and, indeed, the efflux of phospholipids was inhibited (Figure 2A), whereas phospholipid synthesis was accelerated in Nef-transfected cells (Figure 7E). Taken together, these results indicate that HIV-1 infection, via Nef expression, impairs reverse cholesterol transport in macrophages and leads to accumulation of lipids and formation of foam cells.
###end p 29
###begin title 30
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 67 75 <span type="species:ncbi:9606">Patients</span>
HIV-Positive Foam Cells in Atherosclerotic Plaques of HIV-Infected Patients
###end title 30
###begin p 31
###xml 453 454 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">Figure 8</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">8</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">8</xref>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 588 596 588 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">Figure 8</xref>
###xml 686 687 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 732 733 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 741 749 741 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">Figure 8</xref>
###xml 792 793 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 908 909 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 949 957 949 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">Figure 8</xref>
###xml 963 964 963 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">8</xref>
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 106 109 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 399 402 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
###xml 997 1000 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our finding that HIV-1 infection of macrophages impairs cholesterol efflux from these cells suggests that HIV-infected macrophages may potentially contribute to the development of atherosclerotic plaques, especially when combined with dyslipidemia found in PI-treated patients. Immunostaining of sections of atherosclerotic plaques obtained from highly active antiretroviral therapy (HAART)-treated HIV-infected patients demonstrated the presence of p24+ macrophages (Figure 8A, 8B, 8E, and 8F). In areas surrounding lipid cores, some p24+ cells displayed a typical foam cell appearance (Figure 8B). Analysis of parallel consecutive sections stained with anti-CD68 showed that these p24+ cells were located in areas composed of CD68+ cells (Figure 8C), indicating the macrophage nature of p24+ foam cells. Double immunostaining confirmed this notion by demonstrating the association of p24 staining with CD68+ macrophages and macrophage foam cells (Figure 8E and 8F). These findings indicate that HIV-infected, cholesterol-loaded macrophages are present in the atherosclerotic plaque and therefore may potentially be involved in pathophysiological events leading to the development of atherosclerosis.
###end p 31
###begin title 32
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Active Cholesterol Efflux Reduces Infectivity of HIV Virions
###end title 32
###begin p 33
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b047">47</xref>
###xml 577 585 577 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 837 845 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 1436 1444 1436 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 1712 1720 1712 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 306 309 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
###xml 603 606 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 820 825 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 900 903 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1014 1017 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1838 1841 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To determine whether impairment of cholesterol efflux has a role in HIV biology, we compared infectivity of HIV virions produced from monocyte-derived macrophages stimulated or not with an LXR agonist, TO-901317. We hypothesized that if impairment of cholesterol efflux is a specific mechanism to increase HIV replication, then agents counteracting this effect should have anti-HIV activity. LXR agonists up-regulate expression of ABCA1 at a transcriptional level and stimulate cholesterol efflux from various cell types, including human monocyte-derived macrophages ([47] and Figure 9A). When added to HIV-infected macrophages at day 7 after infection and kept with cells for another 7 d (to allow ABCA1 to accumulate and overcome Nef-mediated inhibition), LXR agonist prevented the impairment of cholesterol efflux by HIV-1 infection (Figure 9A); in fact, cholesterol efflux from TO-901317-treated HIV-infected macrophages was similar to efflux from uninfected cells stimulated with the LXR agonist. The lack of HIV-specific reduction of cholesterol efflux is likely due to overproduction of ABCA1, which exceeds production of Nef. Virions were collected from TO-901317-treated and untreated cells, adjusted according to p24 content, and analyzed for infectivity using indicator P4-CCR5 cells. This analysis revealed a substantial reduction (by about 80%) of infectivity of virions produced from macrophages treated with LXR agonist (Figure 9B). Interestingly, protein composition of the virions produced from LXR agonist-treated and untreated cells was very similar (unpublished data), whereas virion-associated cholesterol was significantly diminished in virions produced from TO-901317-treated macrophages (Figure 9C). These results suggest that stimulation of cellular cholesterol efflux may be an effective approach to suppressing HIV replication.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b048">48</xref>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 400 403 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Results presented in this report demonstrate that HIV-1, via the accessory protein Nef, impairs cholesterol efflux from macrophages. This finding can be interpreted as a virus-mediated switch of cholesterol trafficking from physiological efflux to virus-controlled transport, thus reducing the ability of a cell to export excessive cholesterol. Given that availability of cholesterol is critical for HIV assembly and infectivity [48], it is physiologically sensible for the virus to take over control of intracellular cholesterol metabolism.
###end p 35
###begin p 36
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b005">5</xref>
###xml 643 651 643 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">9</xref>
###xml 238 241 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A previous report demonstrated that Nef binds cholesterol and may deliver it to nascent virions [5]. Our study suggests that Nef-mediated impairment of cholesterol efflux is another mechanism ensuring efficient delivery of cholesterol to HIV. Importantly, this mechanism may be a necessary component of the above-mentioned Nef-mediated transport of cholesterol to virions. Indeed, prevention of cholesterol efflux impairment by LXR agonist reduces virion-associated cholesterol without interfering with Nef incorporation into the virions (unpublished data). Reduction of virion-associated cholesterol correlates with lower virion infectivity (Figure 9B and 9C).
###end p 36
###begin p 37
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g002">Figure 2</xref>
###xml 508 516 508 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 869 877 869 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 1030 1038 1030 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 1115 1123 1115 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g009">Figure 9</xref>
###xml 327 332 <span type="species:ncbi:9606">human</span>
###xml 582 585 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 779 782 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 922 925 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1004 1007 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1055 1058 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1205 1208 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1218 1226 <span type="species:ncbi:9606">patients</span>
###xml 1239 1242 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our results demonstrate that Nef specifically targets ABCA1. Indeed, Nef did not suppress cholesterol efflux in cells lacking ABCA1 (HeLa cells or non-activated RAW 264.7 cells), but did so in ABCA1-expressing cells, such as RAW 264.7 cells stimulated with an LXR agonist, HeLa cells transfected with ABCA1, and differentiated human macrophages. Furthermore, Nef did not suppress cholesterol efflux from ABCG1-transfected HeLa cells (Figure 2E). These findings and the fact that Nef can interact with ABCA1 (Figure 5A) suggest that there is an interplay between Nef and ABCA1 in an HIV-infected cell. The end result of this interplay would depend on relative levels of expression of Nef and ABCA1. Consistent with this suggestion, overexpression of Nef from the cytomegalovirus (CMV) promoter inhibits ABCA1-mediated cholesterol efflux stimulated with the LXR agonist (Figure 1C), whereas levels of Nef expressed from the HIV LTR are insufficient to suppress LXR agonist-stimulated cholesterol efflux in HIV-infected macrophages (Figure 9A). As a result, HIV infectivity is reduced in LXR agonist-stimulated cells (Figure 9B). Therefore, drugs stimulating cholesterol efflux may provide a dual benefit to HIV-infected patients by limiting HIV replication and reducing the risk of atherosclerosis.
###end p 37
###begin p 38
###xml 464 473 464 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figures 3</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">5</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b036">36</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b038">38</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b039">39</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b049">49</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b043">43</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b039">39</xref>
###xml 1426 1434 1426 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">Figure 3</xref>
###xml 1440 1441 1440 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g003">3</xref>
###xml 1546 1554 1546 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 1560 1561 1560 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">4</xref>
###xml 1765 1768 1765 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef</italic>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 186 191 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 222 227 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1316 1319 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1401 1406 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1683 1688 <span type="species:ncbi:9606">human</span>
###xml 1705 1708 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1723 1729 <span type="species:ncbi:10090">murine</span>
###xml 1896 1899 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our studies show that cholesterol efflux impairment is a conserved feature of HIV-1 Nef. Indeed, we show this phenomenon using three R5 (ADA, Yu-2, and 92US660) and two X4 (SF2 and LAI) HIV-1 isolates. We demonstrate that HIV-1 Nef impairs cholesterol efflux by at least two mechanisms: it reduces ABCA1 abundance, and it causes intracellular re-distribution of ABCA1. These two mechanisms may be related, as they both depend on interaction between Nef and ABCA1 (Figures 3-5). For example, a block to intracellular trafficking of ABCA1 may re-target this protein to a degradation pathway. Alternatively, ABCA1 re-distribution and down-regulation may be two independent effects of Nef, both contributing to impairment of cholesterol efflux. Indeed, several recent reports demonstrated a role of ABCA1 trafficking between late endosomes and the cell surface in cholesterol efflux from endosomal compartment [36,38,39,49]. The effects of Nef on ABCA1 distribution and apoA-I binding and internalization are similar to the effects of cyclosporin A [43] or deletion of the PEST sequence in ABCA1 [39], both of which inhibit efflux of cholesterol from late endosomes. Therefore, both down-regulation of ABCA1 and its intracellular re-distribution can independently contribute to cholesterol efflux impairment observed in HIV-infected cells. Interestingly, Nef alone had less effect on ABCA1 abundance than HIV-1 infection (compare Figure 3A and 3B), however, it had a more profound effect on the sequestration of ABCA1 at the plasma membrane (compare Figure 4D and 4F). Although this result may be due to differences between the cell types in which these analyses were performed (primary human macrophages for HIV infection and murine macrophage cell line RAW 264.7 for Nef transfection), it is also possible that the primary effect of Nef is to sequester ABCA1 at the plasma membrane, and some other HIV protein may cooperate with Nef to stimulate down-regulation of sequestered ABCA1.
###end p 38
###begin p 39
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b045">45</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b050">50</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b050">50</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b051">51</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b052">52</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b053">53</xref>
###xml 1161 1169 1161 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b054">54</xref>
###xml 826 829 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 908 911 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1295 1300 <span type="species:ncbi:4932">yeast</span>
###xml 1354 1359 <span type="species:ncbi:4932">yeast</span>
The exact molecular mechanisms responsible for the effect of Nef on intracellular trafficking and abundance of ABCA1 are yet to be fully investigated. Nef is known to regulate expression of several transmembrane proteins, including CD4 [45], MHC I [50], MHC II [50], CD28 [51], and DC-SIGN [52]. In most cases, Nef mediates internalization and degradation of the receptor [53], but in some cases (e.g., with DC-SIGN or invariant chain of MHC II), it up-regulates the cell surface expression of the protein. These effects are consistent with our findings showing ABCA1 re-localization and down-regulation, which may involve mechanisms similar to those described for Nef interactions with other proteins. It is worth noting that few of the above-mentioned studies showed co-immunoprecipitation of Nef with a target protein from HIV-infected cells, consistent with our inability to pull down Nef and ABCA1 from HIV-infected macrophages. This may be due to a transitory nature of Nef-ABCA1 interaction and low-level expression of these proteins. Analysis of this interaction in cells overexpressing both proteins demonstrated a critical role of Nef myristoylation (Figure 5A). This fatty acid may either be directly involved in binding of Nef to ABCA1, similar to the role that farnesylation of the yeast pheromone a-factor plays in its interaction with the yeast ABC transporter Ste6 [54], or it may regulate Nef-ABCA1 interaction indirectly by targeting Nef to the plasma membrane. Further analysis of the mechanisms by which Nef affects ABCA1 function would require understanding of the molecular events that regulate intracellular trafficking and degradation of ABCA1 in uninfected cells, which is incompletely characterized and is a subject of the ongoing studies.
###end p 39
###begin p 40
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b055">55</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b007">7</xref>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b009">9</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b014">14</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b019">19</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b027">27</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b028">28</xref>
###xml 1063 1065 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b056">56</xref>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b055">55</xref>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b057">57</xref>
###xml 1418 1420 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b058">58</xref>
###xml 1444 1446 1444 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b059">59</xref>
###xml 1447 1449 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b060">60</xref>
###xml 1500 1502 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b061">61</xref>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b062">62</xref>
###xml 2067 2069 2067 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b063">63</xref>
###xml 2550 2558 2550 2558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g008">Figure 8</xref>
###xml 95 98 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 399 402 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 459 462 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 758 764 <span type="species:ncbi:9606">humans</span>
###xml 1084 1087 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1240 1245 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1278 1281 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1291 1299 <span type="species:ncbi:9606">patients</span>
###xml 1673 1676 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1806 1809 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1938 1941 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2060 2065 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2156 2164 <span type="species:ncbi:9606">patients</span>
###xml 2449 2452 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2518 2526 <span type="species:ncbi:9606">patients</span>
###xml 2734 2737 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2738 2746 <span type="species:ncbi:9606">patients</span>
The results of this study have potential implications for understanding pathogenesis of CAD in HIV-infected patients. These patients have a mildly elevated risk of CAD [55], which is sharply raised by treatment with certain PIs [7,9,14,19]. Increased risk of CAD after treatment with PIs led to the assumption that PIs and/or dyslipidemia are the primary source of development of atherosclerosis in HIV patients. Results presented in this report suggest that HIV-induced impairment of cholesterol efflux from macrophages may be another important contributor to the pathogenesis of CAD. Indeed, inactivation of ABCA1 in macrophages of hyperlipidemic mice significantly increased development of atherosclerosis [27], and genetic mutation inactivating ABCA1 in humans leads to Tangier disease, one of the characteristic features of which is an increased risk of CAD [28]. Impairment of reverse cholesterol transport mediated by down-regulation of ABCA1 has been described for bacterial infections and has been linked to pathogenesis of atherosclerosis (reviewed in [56]). In the case of HIV infection, this mechanism would have only a mild atherogenic effect or not at all on the background of hypocholesterolemia characteristic for untreated HIV-1 infection [55,57]. Treatment of HIV-infected patients with HAART causes a sharp rise of triglyceride-rich VLDL, resulting in enhanced lipid uptake and foam cell formation [58], and small dense LDL [59,60], which is particularly susceptible to oxidation [61], is more able to infiltrate the subendothelial space, and is a risk factor for CAD [62]. A combination of these effects of HAART and impairment of cholesterol efflux by HIV (which prevents compensatory removal of excessive cholesterol) would result in a greatly enhanced accumulation of cholesterol in HIV-infected macrophages and would potentially further increase the risk of development of atherosclerosis. It should be noted that HIV-infected macrophages, unlike T cells, survive for extended periods of time and are considered long-term reservoirs of HIV-1 [63]. As a result, infected macrophages persist, at least for some time, in HAART-treated patients, when conditions favor development of atherosclerotic plaques. We can speculate that these macrophages may contribute to initiation of atherosclerotic plaque formation, which then proceeds even in the absence of newly infected cells. This mechanism is consistent with the presence of HIV-infected macrophages in atherosclerotic plaques of HAART-treated patients observed in our study (Figure 8). However, further in vivo and clinical studies are required to evaluate the contribution of the impairment of reverse cholesterol transport to the risk of atherosclerosis in HIV patients.
###end p 40
###begin p 41
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b064">64</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b066">66</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b024">24</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b025">25</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b025">25</xref>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b012">12</xref>
###xml 209 212 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 253 256 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Findings presented in this report provide an example of how viruses may interfere with cellular cholesterol metabolism and may potentially affect the risk of atherosclerosis. This example may be not unique to HIV. Other viruses (such as Herpes virus or CMV) were found in atherosclerotic plaques and were epidemiologically associated with elevated risk of development of atherosclerosis [64-66]. Future studies will determine whether these viruses cause disturbances in cholesterol metabolism similar to those found in this report. In support of this possibility, several reports demonstrated that bacterial and viral pathogens may modulate macrophage cholesterol efflux by down-regulating ABC transporters via LXR-dependent [24] and LXR-independent [25] pathways. The first pathway is engaged after activation of Toll-like receptors by invading viruses or bacteria. The second pathway involves the negative effect of bacterial endotoxin on ABCA1 mRNA levels in macrophages [25]. Both pathways promote conversion of macrophages into foam cells, which may acquire resistance to pathogen, but retain their atherogenic properties [12]. Therefore, the effect on reverse cholesterol transport may be a common feature of viral and bacterial infection of macrophages, although mechanisms involved are likely unique for each infection.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocyte-derived macrophage cultures.
###end title 43
###begin p 44
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b067">67</xref>
Monocyte-derived macrophages were prepared from peripheral blood mononuclear cells of normal donors using adherence to plastic, and differentiated in the presence of macrophage colony-stimulating factor essentially as previously described [67]. No stimulation with LXR agonist was performed unless indicated.
###end p 44
###begin title 45
Antibodies.
###end title 45
###begin p 46
###xml 57 63 <span type="species:ncbi:9986">rabbit</span>
###xml 143 149 <span type="species:ncbi:9986">rabbit</span>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 238 244 <span type="species:ncbi:9986">rabbit</span>
###xml 288 294 <span type="species:ncbi:9986">rabbit</span>
###xml 342 347 <span type="species:ncbi:10090">mouse</span>
The following antibodies were used for Western blotting: rabbit polyclonal anti-ABCA1 (Novus Biologicals, Littleton, Colorado, United States), rabbit polyclonal and mouse monoclonal anti-Nef (AIDS Research and Reference Reagent Program), rabbit polyclonal anti-ABCG1 (Novus Biologicals), rabbit polyclonal anti-SR-B1 (Novus Biologicals), and mouse monoclonal anti-beta-actin (Sigma, St. Louis, Missouri, United States).
###end p 46
###begin title 47
Viruses and infections.
###end title 47
###begin p 48
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b005">5</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b068">68</xref>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 243 248 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophage-tropic HIV-1 strains Yu-2 and 92US660 were obtained from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program. VSV-G-pseudotyped HIV-1 was prepared by co-transfecting HEK 293T cells with Env-deficient HIV-1 infectious clones [5] and VSV-G-expressing plasmid pHEF-VSVG [68]. All infections were performed using 3.5 x 106 cpm of RT activity per 106 cells.
###end p 48
###begin title 49
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
FACS analysis of HIV-infected macrophages.
###end title 49
###begin p 50
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 54 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To determine the percentage of HIV-infected cells, HIV-infected macrophages were detached from the plate, fixed in 4% formalin/PBS, permeabilized using Becton-Dickinson permeabilization/washing solution (15 min at 4 degreesC), and incubated with PE-conjugated anti-p24 monoclonal antibodies (mAb) or isotype control IgG for 30 min at 4 degreesC. After washing, cells were analyzed on a FACScan flow cytometer (Becton-Dickinson, Palo Alto, California, United States).
###end p 50
###begin title 51
Transfection.
###end title 51
###begin p 52
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b069">69</xref>
###xml 10 15 <span type="species:ncbi:10090">mouse</span>
RAW 264.7 mouse macrophage cells were transiently transfected using the DEAE-dextran method and 5-azacytidine as described previously [69]. The efficiency of transfection was 80%-90%. HEK 293T and HeLa cells were transfected using Metafectene reagent (Biontex, Munich, Germany) following the manufacturer's protocol. The efficiency of transfection was 80%.
###end p 52
###begin title 53
Cholesterol and phospholipid efflux from RAW 264.7 cells.
###end title 53
###begin p 54
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 508 510 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b070">70</xref>
###xml 699 701 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b071">71</xref>
RAW 264.7 cells were incubated in labeling medium containing [3H]cholesterol (75 kBq/ml) or [methyl-14C]choline (0.2 MBq/ml) for 48 h. Cells were then incubated for 18 h in serum-free medium in the presence of the LXR agonist TO-901317 (final concentration 1 muM) to stimulate ABCA1 expression and cholesterol efflux. Cells were then washed with PBS and incubated for 3 h in either serum-free medium alone (blank) or in serum-free medium supplemented with 30 mug/ml of lipid-free apoA-I or 30 mug/ml of HDL [70]. For cholesterol efflux analysis, aliquots of medium and cells were counted. Phospholipids were isolated from medium and cells by thin layer chromatography (TLC) as described previously [71]. The efflux was calculated as radioactivity in the medium/(radioactivity in the medium + radioactivity remaining in the cells) x 100%. ApoA-I-dependent efflux is efflux to apoA-I minus efflux to blank.
###end p 54
###begin title 55
Cholesterol efflux from monocyte-derived macrophages and HeLa cells.
###end title 55
###begin p 56
###xml 251 256 <span type="species:ncbi:9606">human</span>
The same procedure as described above was used except that cells were not stimulated with LXR agonist, and efflux was allowed to proceed for 12 h rather than the 3 h used for RAW 264.7 cells. Efflux to serum-free medium supplemented with 30 mug/ml of human serum albumin was used as a control.
###end p 56
###begin title 57
Phospholipid biosynthesis.
###end title 57
###begin p 58
###xml 71 73 71 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b071">71</xref>
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
RAW 264.7 cells were incubated in serum-free medium containing [methyl-14C]choline (0.2 MBq/ml) for 2 h. Cells were washed, and lipids were extracted and separated by TLC [71]. Phospholipid biosynthesis was defined as incorporation of [14C]choline into phospholipids per mg of cell protein per 2 h.
###end p 58
###begin title 59
Cholesteryl ester and triglyceride biosynthesis and content.
###end title 59
###begin p 60
###xml 223 225 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 336 338 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 460 462 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b072">72</xref>
###xml 136 141 <span type="species:ncbi:9606">human</span>
RAW 264.7 cells were incubated with or without AcLDL (50 mug/ml) in the presence of 30 mug/ml of lipid-free apoA-I or 5% normolipidemic human plasma for 2 h at 37 degreesC. Cells were then incubated for 2 h with 37 kBq/ml [14C]oleic acid (presented to the cells as a BSA-sodium oleate complex). Cells were washed, lipids extracted and [14C]oleic acid incorporation into cholesteryl esters and triglyceride was measured after separation of the extracts by TLC [72]. Cellular free and total cholesterol content were measured using enzymatic assay (Roche, Basel, Switzerland). Free cholesterol content was calculated as a difference between total and esterified cholesterol.
###end p 60
###begin title 61
AcLDL uptake.
###end title 61
###begin p 62
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 231 234 231 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 391 394 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 608 611 601 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
AcLDL was labeled with 125I using Iodobeads (Pierce Biotechnology, Rockford, Illinois, United States) according to the manufacturer' instructions, the final specific radioactivity was 100 cpm/ng protein. Cells were incubated with [125I]AcLDL at the final concentration 5 mug/ml in the presence or absence of 100-fold excess of unlabeled AcLDL for 2 h at 37 degreesC. The amount of degraded [125I]AcLDL in the medium was determined as non-iodine trichloroacetic acid-soluble radioactivity. Cells were then washed and counted, and specific AcLDL uptake was calculated as a sum of cell-associated and degraded [125I]AcLDL after subtraction of non-specific binding and degradation (i.e., measured in the presence of unlabeled AcLDL).
###end p 62
###begin title 63
ApoA-I binding, internalization, and degradation.
###end title 63
###begin p 64
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 300 303 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 500 503 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human apoA-I was labeled with 125I using Iodobeads; the final specific radioactivity was 200-cpm/ng protein. Cells were incubated with [125I]apoA-I at the final concentration 2 mug/ml in the presence or absence of a 100-fold excess of unlabeled apoA-I for 2 h at 37 degreesC. The amount of degraded [125I]apoA-I in the medium was determined as non-iodine trichloroacetic acid-soluble radioactivity. Cells were then washed, treated with 0.05% trypsin for 5 min at 37 degreesC to remove surface-bound [125I]apoA-I, and centrifuged. Radioactivity in supernatant (binding) and pellet (internalization) was counted, and specific apoA-I binding, internalization, and degradation were calculated after subtraction of non-specific values measured in the presence of unlabeled apoA-I.
###end p 64
###begin title 65
Co-immunoprecipitation of Nef and ABCA1.
###end title 65
###begin p 66
HeLa cells were co-transfected with ABCA1-FLAG and Nef. At 48-h post-transfection, cells were homogenized in PBS, and batch immunoprecipitations using M2 affinity gel (Sigma) were carried out according to the manufacturer's protocol. Immunoprecipitate was analyzed by Western blotting using polyclonal anti-ABCA1 (Novus Biologicals) and anti-Nef (AIDS Research and Reference Reagent Program) antibodies.
###end p 66
###begin title 67
Oil Red O Staining.
###end title 67
###begin p 68
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocyte-derived macrophages and RAW 264.7 cells (stimulated with LXR agonist) were incubated with AcLDL (50 mug/ml) in RPMI 1640 supplemented with 1% Nutridoma (Roche) and 30 mug/ml of lipid-free apoA-I for 18 h. After washing with PBS, cells were fixed in 3.7% formaldehyde for 2 min, washed with water, and incubated at room temperature for 1 h with Oil Red O working solution (Fisher Biotech, West Perth, Australia). The Oil Red O solution was removed by aspiration, the cells were washed with water, and 0.02% sodium azide was added to the cells. The cells were observed using a reflecting light microscope (90x magnification) fitted with a camera.
###end p 68
###begin title 69
Fluorescent Microscopy.
###end title 69
###begin p 70
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b073">73</xref>
###xml 294 299 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 622 626 <span type="species:ncbi:9925">goat</span>
###xml 665 671 <span type="species:ncbi:9986">rabbit</span>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
###xml 780 784 <span type="species:ncbi:9925">goat</span>
###xml 1027 1033 <span type="species:ncbi:9986">rabbit</span>
###xml 1059 1064 <span type="species:ncbi:10090">mouse</span>
For visualization of ABCA1 localization, approximately 106 monocyte-derived macrophages were plated into each well of a 24-well plate containing polylysine-coated coverslips (Becton Dickinson Labware, Bedford, Massachusetts, United States) and infected with VSV-G pseudotyped WT or Nef-deleted HIV-1 viruses, or left uninfected. At 5-d post-infection, coverslips with adherent macrophages were removed from the wells and washed with PBS, and cells were fixed with 4% formaldehyde (in PBS) for 20 min at room temperature. After fixing, cells were washed three times with PBS and incubated for 1 h at room temperature in 4% goat serum (in PBS). After washing in PBS, rabbit polyclonal antibody to ABCA1 (Novus Biologicals) and mouse monoclonal antibody to p24 [73] were added in 4% goat serum, 0.1% BSA, and 0.1% Saponin. Anti-ABCA1 antibody was added at a 1:500 dilution and anti-p24 antibody, at 1:100. Following a 2-h incubation at room temperature, the coverslips were washed with PBS and incubated with Cy-5-conjugated anti-rabbit and FITC-conjugated anti-mouse secondary antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania, United States) for 1 h at room temperature. Coverslips were mounted onto slides using Prolong (Molecular Probes, Eugene, Oregon, United States) and allowed to dry overnight. Visualization of stained cells was accomplished using a Bio-Rad MRC 1024 confocal laser scanning microscope and software (Bio-Rad, Hercules, California, United States).
###end p 70
###begin p 71
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 462 466 <span type="species:ncbi:9925">goat</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 637 642 <span type="species:ncbi:10090">mouse</span>
###xml 693 699 <span type="species:ncbi:9986">rabbit</span>
RAW 264.7 cells (LXR agonist-stimulated) were grown on collagen-coated coverslips and transfected with Nef-expressing construct or an empty vector. Cells were cultured for 48 h prior to immunostaining, washed with PBS, fixed with 4% formaldehyde, and quenched with 50 mM NH4Cl. After permeabilization with 0.5% Triton X-100, cells were incubated with the monoclonal anti-ABCA1 antibody NDF4C2 for 1 h, washed with PBS, and incubated in the dark with a secondary goat anti-mouse FITC-labeled antibody for 1 h. For co-localization analysis, monoclonal anti-ABCA1 and polyclonal anti-Nef antibody were used, followed by Cy5-conjugated anti-mouse (staining ABCA1 in blue) and FITC-conjugated anti-rabbit (staining Nef in green) antibodies. Cells were washed again with PBS and, after mounting onto glass slides, were studied using Zeiss META confocal microscope (Zeiss, Oberkochen, Germany). Image analysis was performed using the LSM 510 software of the Zeiss microscope which analyzes the distribution of the fluorescence along cell section.
###end p 71
###begin title 72
Transmission electron microscopy.
###end title 72
###begin p 73
###xml 31 34 31 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophages infected with HIV-1ADA were fixed in 2.5% neutral-buffered glutaraldehyde, pelleted, gelled into agar, post-fixed in 1% OsO4, block-stained in uranyl acetate, dehydrated in graded ethanol and propylene oxide, and embedded in Spurr's resin. Thin sections were stained with uranylacetate and lead citrate, and examined on a LEO EM10 electron microscope (LEO Electron Microscopy, Thornwood, New Jersey, United States) at 60 kV.
###end p 73
###begin title 74
Real-Time RT-PCR.
###end title 74
###begin p 75
###xml 561 563 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b035">35</xref>
###xml 903 905 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b072">72</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
cDNA was prepared from total cellular RNA from human monocyte-derived macrophages and analyzed by QPCR using IQ Sybr Green Supermix from Bio-Rad according to the manufacturer's recommendations with the following primers (300 nM of each primer per sample): ABCA1 sense, 5'-GAGCCTCCCCAGGAGTCG-3'; ABCA1 antisense, 5'-CAAACATGTCAGCTGTTACTGGAAG-3'; beta-actin sense, 5'- GCCGTACCACTGGCATCGTG-3'; beta-actin antisense, 5'-GTGGTGGTGAAGCTGTA-3'. Primers were ordered from Integration DNA Technologies (Coralville, Iowa, United States). Serial dilutions of ABCA1-pTRE [35] and beta-actin cDNA (QPCR Plasmid Standard from Invitrogen, Carlsbad, California, United States) plasmids were used to calculate the copy number of ABCA1 and beta-actin cDNA per sample, and results were adjusted according to beta-actin cDNA levels. The abundance of ABCA1-specific RNA in RAW cells was determined as described previously [72].
###end p 75
###begin title 76
Autopsies.
###end title 76
###begin p 77
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b074">74</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 315 320 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
Segments of the aortic wall were removed at autopsy from four HAART-treated AIDS patients (males, aged 39, 40, 44, and 47 y) at the Institute of Forensic Medicine, Sydney, Australia. The specimens were fixed in formalin and embedded in paraffin. Parallel sections were immunostained with the p24 antibody to detect HIV-1, and anti-CD68 antibody to identify macrophages. Single and double (using DAKO-DOUBLESTAIN Kit System 40; Dako, Glostrup, Denmark) immunostaining was carried out as described previously [74]. Sections of lymph nodes excised from the AIDS patients served as a positive control.
###end p 77
###begin title 78
Infectivity assay.
###end title 78
###begin p 79
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040365-b075">75</xref>
###xml 115 120 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Virus infectivity was analyzed using P4-CCR5 indicator cells [75] that express beta-galactosidase under control of HIV-1 LTR. Briefly, cells were seeded into a 96-well plate at a density of 7,500 cells per well and allowed to adhere overnight. The medium was then removed and replaced with virus in suspension (normalized according to RT activity) or with fresh medium as a control. Infection was allowed to proceed for 48 h at 37 degreesC, then the virus was removed, and 100 mul of lysis buffer (beta-Galactosidase Enzyme Assay System; Promega, Madison, Wisconsin, United States) was added. The plate was then frozen overnight at -70 degreesC to ensure efficient lysis. Upon thawing, 50 mul of lysate was placed into a new 96-well plate, and 50 mul of 2x Assay Buffer was added. The plate was incubated at 37 degreesC for 1.5 h and optical density (OD) readings were taken at 420 nm.
###end p 79
###begin title 80
Analysis of virion-associated cholesterol.
###end title 80
###begin p 81
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 509 510 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Seven days post-infection with HIV-ADA, [3H]cholesterol was added to the cultures at a final concentration of 75 kBq/ml. At 24 h after addition of cholesterol, the labeled medium was removed, the cells were washed with PBS, and the new medium was added with or without 500 nM of LXR agonist, TO-901317 (Sigma). Culture supernatants were collected every 3 d over the period of 2 wk and pooled; virions were pelleted by ultracentrifugation and normalized according to p24 value, and the amount of incorporated [3H]cholesterol was counted on a beta-counter.
###end p 81
###begin title 82
Statistical analysis.
###end title 82
###begin p 83
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
All experiments were reproduced two to four times, and representative experiments are shown. The Student t test was used to determine statistical significance of the differences.
###end p 83
###begin title 84
Supporting Information
###end title 84
###begin title 85
Accession Numbers
###end title 85
###begin p 86
The Swiss-Prot () accession numbers for the proteins discussed in this paper are ABCA1 (O95477), ABCG1 (P45844), LAI-derived Nef (P03406), and SF2-derived Nef (P03407).
###end p 86
###begin p 87
###xml 74 77 70 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF2</sub>
###xml 89 92 85 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF2</sub>
###xml 166 169 158 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 677 683 <span type="species:ncbi:9986">rabbit</span>
###xml 764 769 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 807 812 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 908 913 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We are grateful to Dr. Matija Peterlin for pHSF2Nef, pHSF2NefDeltaXho, NefSF2, and NefG2ASF2 constructs; to Dr. Olivier Schwartz for AD8, AD8DeltaNef viruses, and NefLAI expression construct; to Dr. Michael Fitzgerald for ABCA1-FLAG; and to Dr. Alan Remaley for the ABCA1-GFP and ABCG1-GFP constructs and HDL preparations. We thank Stephanie J. Inder for assistance in the collection of autopsy specimens. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH: pHEF-VSVG from Dr. Lung-Ji Chang; monoclonal anti-Nef antibodies EH1 from Dr. James Hoxie; rabbit polyclonal anti-Nef antiserum from Dr. Ronald Swanstrom; monoclonal antibody to HIV-1 p24 (AG3.0) from Dr. Jonathan Allan; HIV-1 strain 92US660 from the Multi-Center AIDS Cohort Study and the NIAID Division of AIDS (DAIDS); HIV-1 strain Yu-2 from Beatrice Hahn and George Shaw; and P4-CCR5 cells from Dr. Nathaniel Landau and Dr. Pierre Charneau.
###end p 87
###begin p 88
ZM and MPM are predoctoral students in the Biochemistry & Molecular Biology and Immunology Programs, respectively, of the Institute for Biomedical Sciences at the George Washington University. This work is part of their dissertations to be presented to the above programs in partial fulfillment of the requirements for the Ph.D. degree.
###end p 88
###begin title 89
Abbreviations
###end title 89
###begin p 90
ATP-binding cassette transporter A1
###end p 90
###begin p 91
acetylated low-density lipoprotein
###end p 91
###begin p 92
apolipoprotein A-I
###end p 92
###begin p 93
coronary artery disease
###end p 93
###begin p 94
dendritic cell-specific ICAM-3-grabbing nonintegrin
###end p 94
###begin p 95
highly active antiretroviral therapy
###end p 95
###begin p 96
high-density lipoprotein
###end p 96
###begin p 97
low-density lipoprotein
###end p 97
###begin p 98
liver X receptor
###end p 98
###begin p 99
major histocompatibility complex
###end p 99
###begin p 100
protease inhibitor
###end p 100
###begin p 101
reverse transcription
###end p 101
###begin p 102
standard deviation
###end p 102
###begin p 103
scavenger receptor B1
###end p 103
###begin p 104
###xml 0 26 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
vesicular stomatitis virus
###end p 104
###begin p 105
wild type
###end p 105
###begin p 106
Nef deficient
###end p 106
###begin title 107
References
###end title 107
###begin article-title 108
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium
###end article-title 108
###begin article-title 109
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Plasma membrane rafts play a critical role in HIV-1 assembly and release
###end article-title 109
###begin article-title 110
###xml 65 70 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity
###end article-title 110
###begin article-title 111
###xml 9 44 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization
###end article-title 111
###begin article-title 112
###xml 77 82 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions
###end article-title 112
###begin article-title 113
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cardiovascular manifestations of HIV infection
###end article-title 113
###begin article-title 114
###xml 11 14 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort
###end article-title 114
###begin article-title 115
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Coronary artery disease in HIV infected patients
###end article-title 115
###begin article-title 116
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 94 97 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection
###end article-title 116
###begin article-title 117
###xml 18 46 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction
###end article-title 117
###begin article-title 118
Atherosclerosis
###end article-title 118
###begin article-title 119
###xml 39 59 39 59 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Chlamydia pneumoniae</named-content>
###xml 83 103 83 103 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Chlamydia pneumoniae</named-content>
###xml 39 59 <span type="species:ncbi:83558">Chlamydia pneumoniae</span>
###xml 83 103 <span type="species:ncbi:83558">Chlamydia pneumoniae</span>
Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines
###end article-title 119
###begin article-title 120
###xml 63 91 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
###end article-title 120
###begin article-title 121
Abnormal lipids and the acquired immunodeficiency syndrome: Is there a problem and what should we do about it?
###end article-title 121
###begin article-title 122
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
###end article-title 122
###begin article-title 123
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis
###end article-title 123
###begin article-title 124
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages
###end article-title 124
###begin article-title 125
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
###end article-title 125
###begin article-title 126
###xml 62 65 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 75 83 <span type="species:ncbi:9606">children</span>
Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy
###end article-title 126
###begin article-title 127
###xml 35 42 <span type="species:ncbi:9606">persons</span>
###xml 48 76 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Ischemic cardiovascular disease in persons with human immunodeficiency virus infection
###end article-title 127
###begin article-title 128
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 142 145 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection
###end article-title 128
###begin article-title 129
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 54 82 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Acute myocardial infarction in patients infected with human immunodeficiency virus
###end article-title 129
###begin article-title 130
Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages
###end article-title 130
###begin article-title 131
Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism
###end article-title 131
###begin article-title 132
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
###xml 84 90 <span type="species:ncbi:10090">murine</span>
Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: Differential role of LXR
###end article-title 132
###begin article-title 133
ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity
###end article-title 133
###begin article-title 134
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages
###end article-title 134
###begin article-title 135
Tangier disease and ABCA1
###end article-title 135
###begin article-title 136
Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis
###end article-title 136
###begin article-title 137
###xml 39 67 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes
###end article-title 137
###begin article-title 138
###xml 13 48 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 80 106 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 115 120 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A
###end article-title 138
###begin article-title 139
###xml 11 21 <span type="species:ncbi:111938">gatekeeper</span>
ABCA1. The gatekeeper for eliminating excess tissue cholesterol
###end article-title 139
###begin article-title 140
ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation
###end article-title 140
###begin article-title 141
HDL apolipoproteins and ABCA1: Partners in the removal of excess cellular cholesterol
###end article-title 141
###begin article-title 142
###xml 51 56 <span type="species:ncbi:9606">human</span>
Apolipoprotein specificity for lipid efflux by the human ABCAI transporter
###end article-title 142
###begin article-title 143
###xml 45 50 <span type="species:ncbi:9606">human</span>
Cellular localization and trafficking of the human ABCA1 transporter
###end article-title 143
###begin article-title 144
ABCA1 expression in carotid atherosclerotic plaques
###end article-title 144
###begin article-title 145
The ABCA1 transporter modulates late endocytic trafficking: Insights from the correction of the genetic defect in Tangier disease
###end article-title 145
###begin article-title 146
A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes
###end article-title 146
###begin article-title 147
Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1
###end article-title 147
###begin article-title 148
ABCA1 Is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages
###end article-title 148
###begin article-title 149
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1)
###end article-title 149
###begin article-title 150
Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I
###end article-title 150
###begin article-title 151
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: Role of the acidic residue in the ExxxLL motif
###end article-title 151
###begin article-title 152
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef
###end article-title 152
###begin article-title 153
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Nef disrupts antigen presentation early in the secretory pathway
###end article-title 153
###begin article-title 154
A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux
###end article-title 154
###begin article-title 155
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1
###end article-title 155
###begin article-title 156
Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes
###end article-title 156
###begin article-title 157
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
###end article-title 157
###begin article-title 158
Mechanism for down-regulation of CD28 by Nef
###end article-title 158
###begin article-title 159
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread
###end article-title 159
###begin article-title 160
Nef: Agent of cell subversion
###end article-title 160
###begin article-title 161
Consequences of altered isoprenylation targets on a-factor export and bioactivity
###end article-title 161
###begin article-title 162
###xml 10 13 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 53 56 <span type="species:ncbi:9606">men</span>
Impact of HIV infection and HAART on serum lipids in men
###end article-title 162
###begin article-title 163
Thematic review series: The pathogenesis of atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host
###end article-title 163
###begin article-title 164
###xml 67 95 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection
###end article-title 164
###begin article-title 165
###xml 130 135 <span type="species:ncbi:9606">human</span>
Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor
###end article-title 165
###begin article-title 166
###xml 7 35 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction
###end article-title 166
###begin article-title 167
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: An index of atherogenicity?
###end article-title 167
###begin article-title 168
Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
###end article-title 168
###begin article-title 169
Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease
###end article-title 169
###begin article-title 170
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 81 109 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus
###end article-title 170
###begin article-title 171
Evidence for infectious agents in cardiovascular disease and atherosclerosis
###end article-title 171
###begin article-title 172
Microorganisms in the aetiology of atherosclerosis
###end article-title 172
###begin article-title 173
Do pathogens accelerate atherosclerosis?
###end article-title 173
###begin article-title 174
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cell proliferation is not required for productive HIV-1 infection of macrophages
###end article-title 174
###begin article-title 175
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system
###end article-title 175
###begin article-title 176
Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages
###end article-title 176
###begin article-title 177
Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants
###end article-title 177
###begin article-title 178
Structure-function studies of apoA-I variants: Site-directed mutagenesis and natural mutations
###end article-title 178
###begin article-title 179
Expression of caveolin-1 enhances cholesterol efflux in hepatic cells
###end article-title 179
###begin article-title 180
###xml 38 73 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes
###end article-title 180
###begin article-title 181
Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions
###end article-title 181
###begin article-title 182
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 reverse transcription. A termination step at the center of the genome
###end article-title 182
###begin title 183
Figures and Tables
###end title 183
###begin title 184
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Nef Impairs Cholesterol Efflux from Macrophages
###end title 184
###begin p 185
###xml 377 398 376 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 584 585 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Monocyte-derived macrophages were inoculated with indicated HIV-1 strains equalized according to RT activity and cultivated for 21 d (RT activity in the culture supernatants on day 21 is shown beneath the bars). Mock-infected cells were incubated with virus-free medium. Specific cholesterol efflux to apoA-I (30 mug/ml) was performed for 12 h and analyzed as described in Materials and Methods. Results are presented as percentage of efflux from mock-infected cells (taken as 100%) and are mean +/- standard deviation (SD) of triplicate determinations. An asterisk (*) indicates p < 0.001
###end p 185
###begin p 186
###xml 516 517 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) Monocyte-derived macrophages were inoculated with VSV-G-pseudotyped HIV-1 SF2 either deficient in Nef (SF2.DeltaNef) or carrying WT Nef (SF2.wt). Specific cholesterol efflux to apoA-I (30 mug/ml) was analyzed on day 6 after inoculation using the same procedure as described in (A). p24 concentration in the culture medium is shown beneath the bars. Results are presented as percentage of efflux from mock-infected cells (taken as 100%) and are mean +/- SD of triplicate determinations. An asterisk (*) indicates p < 0.001.
###end p 186
###begin p 187
###xml 324 345 322 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 429 430 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C) RAW 264.7 cells were transfected with plasmids expressing indicated Nef variants or an empty vector (mock-transfection). Twenty-four hours after transfection, LXR agonist, TO-901317 (1 mumol/L), was added. Cholesterol efflux to apoA-I (30 mug/ml) was performed for 3 h with cells 48 h after transfection as described in Materials and Methods. Means +/- SD of quadruplicate determinations are shown. An asterisk (*) indicates p < 0.001.
###end p 187
###begin p 188
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(D) Immunoblotting of RAW 264.7 cells transfected with empty vector (mock), WT Nef derived from HIV-1 strain SF2 (Nef.wt), or Nef.G2A mutant, and stained with anti-Nef antibodies.
###end p 188
###begin title 189
Nef Targets ABCA1-Dependent Cholesterol Efflux
###end title 189
###begin p 190
###xml 150 158 149 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Cholesterol efflux to HDL (30 mug/ml) was measured from HIV-1 ADA-infected and mock-infected macrophages used also to measure efflux to apoA-I in Figure 1A.
###end p 190
###begin p 191
###xml 261 268 260 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 352 353 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 131 136 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) Impairment of phospholipid efflux in Nef-transfected RAW 264.7 cells. RAW 264.7 cells were transfected with plasmid expressing HIV-1 SF2-derived Nef or empty vector (mock-transfection). Phospholipid efflux to apoA-I (30 mug/ml) was measured as described in Methods. Means +/- SD of quadruplicate determinations are shown. An asterisk (*) indicates p < 0.001.
###end p 191
###begin p 192
###xml 163 171 163 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g001">Figure 1</xref>
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(C) Nef does not decrease cholesterol efflux in RAW 264.7 cells not treated with LXR agonist. Experiment was performed using HIV-1 SF2-derived Nef as described in Figure 1C, except that LXR agonist was not added.
###end p 192
###begin p 193
###xml 319 320 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 190 195 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(D) Cholesterol efflux to apoA-I from HeLa cells. HeLa cells were either mock-transfected (mock) or co-transfected with ABCA1 and empty vector (ABCA1), or vector expressing Nef derived from HIV-1 SF2 (ABCA1 + NefSF2) or LAI strains (ABCA1 + NefLAI); cholesterol efflux to apoA-I was analyzed. An asterisk (*) indicates p < 0.001 (versus cells without ABCA1); a number sign (#) indicates p < 0.001 (versus cells without Nef). Expression of Nef determined by Western blot is shown beneath the bars.
###end p 193
###begin p 194
###xml 226 227 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(E) Cholesterol efflux to HDL from HeLa cells. Experiment was performed as in (D), except that ABCG1 was used instead of ABCA1, and HDL (30 mug/ml) instead of apoA-I was used as cholesterol acceptor. An asterisk (*) indicates p < 0.01 (versus cells without ABCG1).
###end p 194
###begin title 195
Nef Induces Down-Modulation of ABCA1
###end title 195
###begin p 196
###xml 4 9 <span type="species:ncbi:9606">Human</span>
###xml 58 63 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Human monocyte-derived macrophages were infected with HIV-1 ADA or mock-infected and cultured for 14 d (RT in culture supernatant was 4,000 cpm/mul). ABCA1, ABCG1, SR-B1, and beta-actin (loading control) were analyzed by Western blotting.
###end p 196
###begin p 197
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) RAW 264.7 cells were transfected with vector expressing HIV-1 SF2-derived Nef (either WT or carrying a G2A mutation) or empty vector (mock). Twenty-four hours after transfection, cells were stimulated with TO-901317 (1 muM) and 24 h later, were analyzed by Western blotting for ABCA1 and beta-actin (loading control).
###end p 197
###begin p 198
###xml 228 229 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(C) ABCA1 RNA from HIV-infected macrophages used for Western blotting in (A) was analyzed by real-time RT-PCR. Results were adjusted according to beta-actin signal and are presented in arbitrary units; an asterisk (*) indicates p < 0.01 (versus mock).
###end p 198
###begin p 199
###xml 372 373 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(D) RNA was extracted from non-activated RAW 264.7 cells (control), mock-transfected RAW cells activated with LXR agonist TO-901317 (LXR), or cells transfected with SF2-derived Nef and activated with TO-901317 (LXR+NefSF2), and analyzed by real-time RT-PCR. Results were adjusted according to 28S RNA signal and are presented in arbitrary units; an asterisk (*) indicates p < 0.01 (versus LXR agonist-treated, mock-transfected cells).
###end p 199
###begin title 200
The Effect of Nef on ABCA1 Localization
###end title 200
###begin p 201
###xml 101 106 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 180 186 <span type="species:ncbi:9986">rabbit</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
###xml 283 289 <span type="species:ncbi:9986">rabbit</span>
(A-D) On day 5 after infection with VSV-G-pseudotyped Nef-expressing (B and D) or DeltaNef (A and C) HIV-1 SF2, cells were co-stained with anti-p24 mouse monoclonal and anti-ABCA1 rabbit polyclonal antibodies, followed by FITC-conjugated anti-mouse (A and B) and Cy5-conjugated anti-rabbit IgG (C and D). Arrows point to cells with re-localized ABCA1. The scale bars represent 20 mum.
###end p 201
###begin p 202
###xml 205 212 205 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef.wt,</italic>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nef.G2A</italic>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
###xml 198 203 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(E-G) Distribution of ABCA1 revealed by staining with monoclonal anti-ABCA1 antibody and FITC-conjugated anti-mouse IgG in RAW 264.7 cells transfected with empty vector (E), WT Nef derived from SF2 HIV-1 (Nef.wt, panel [F]), or SF2 Nef carrying a G2A mutation (Nef.G2A, [G]). Insets in (E and F) show cross-section of the image reconstituted from serial sectioning. Scale bars represent 20 mum.
###end p 202
###begin p 203
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 115 120 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(H) [125-I]apoA-I binding (left panel) and internalization (right panel) in RAW 264.7 macrophages transfected with HIV-1 SF2-derived Nef. An asterisk (*) indicates p < 0.01.
###end p 203
###begin title 204
Nef Interacts with ABCA1
###end title 204
###begin p 205
(A) ABCA1 was immunoprecipitated using anti-FLAG M2 affinity gel from HeLa cells co-transfected with ABCA1-FLAG and an empty vector (mock), WT SF2 Nef (Nef.wt), or myristoylation-defective mutant Nef.G2A. Immunoprecipitates were analyzed by Western blotting for Nef (upper panel) or ABCA1 (middle panel) using specific antibodies. Bottom panel shows Nef expression in lysates of cells used for immunoprecipitation.
###end p 205
###begin p 206
###xml 35 43 35 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 281 289 281 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g004">Figure 4</xref>
###xml 173 179 <span type="species:ncbi:9986">rabbit</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
(B) Experiment was performed as in Figure 4E, except that cells were incubated with monoclonal anti-ABCA1 and polyclonal anti-Nef antibody, followed by FITC-conjugated anti-rabbit and Cy5-conjugated anti-mouse antibodies. Since all transfected cells show re-localization of ABCA1 (Figure 4E), a typical single cell is shown here. Images were analyzed using software on the Zeiss LSM 510 microscope. The scale bar represents 20 mum.
###end p 206
###begin p 207
###xml 41 49 41 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040365-g005">Figure 5</xref>
###xml 147 152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(C) Fluorescence profile of the image in Figure 5B was analyzed using the LSM 510 software. The top panel shows the distributions of the ABCA1 and HIV-1 Nef proteins in blue and green, respectively. The same analysis in the lower panel was performed for ABCA1 (blue) and Nef.G2A (green). The co-localization of WT Nef and ABCA1 at the plasma membrane is indicated by overlapping green and blue peaks at either end of the graph in the top panel.
###end p 207
###begin title 208
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Accumulation of Lipids in Cells Infected with HIV-1 or Transfected with Nef
###end title 208
###begin p 209
###xml 28 31 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 155 160 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 515 520 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A-C) Oil Red O staining of HIV-infected macrophages. Uninfected (A) macrophages or cells infected with VSV-G-pseudotyped Nef-positive (B) or DeltaNef (C) HIV-1 SF2 variants were loaded with cholesterol on day 3 after infection by incubating with AcLDL in the presence of apoA-I, and lipids were stained with Oil Red O 24 h later. p24 concentration in the culture supernatant on day 3 after infection was 4.7 ng/ml for cells inoculated with Nef-positive virus and 9.8 ng/ml for the culture inoculated with DeltaNef HIV-1.
###end p 209
###begin p 210
###xml 133 138 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(D-F) Electron microscopy of cholesterol-loaded uninfected macrophages (D) and cells infected with Nef-positive (E) and DeltaNef (F) HIV-1 AD8 performed 14 d after infection. Uninfected cells have small numbers of electron-lucent lipid vacuoles (arrows). The cytoplasm of cells infected with Nef-positive virus is filled with electron-dense lipid vacuoles (arrows). Cells infected with DeltaNef virus have small numbers of electron-lucent lipid vacuoles (arrows), similar in number to those in uninfected cells. The scale bars represent 5 mum.
###end p 210
###begin p 211
###xml 361 362 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 261 266 <span type="species:ncbi:9606">human</span>
(G) The effect of Nef on cholesteryl ester synthesis. The rate of cholesteryl ester synthesis in RAW 264.7 cells transfected with an empty vector (mock-transfected) or Nef-expressing construct and incubated with or without AcLDL in the presence of apoA-I or 5% human plasma is presented as mean +/- SD of quadruplicate determinations. An asterisk (*) indicates p < 0.02.
###end p 211
###begin p 212
(H) and (I) RAW 264.7 cells were transfected with empty vector (H) or Nef-expressing construct (I), stimulated with LXR agonist, incubated with AcLDL and lipid-free apoA-I, fixed with formaldehyde, and stained with Oil Red O.
###end p 212
###begin title 213
Analysis of Lipids in RAW 264.7 Macrophages Transfected with Nef
###end title 213
###begin p 214
###xml 132 133 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A) Cholesteryl ester content after 24 h incubation with AcLDL (50 mug/ml) determined by enzymatic assay; an asterisk (*) indicates p < 0.01.
###end p 214
###begin p 215
###xml 131 132 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(B) Free cholesterol content after 24 h incubation with AcLDL (50 mug/ml) determined by enzymatic assay; an asterisk (*) indicates p < 0.05.
###end p 215
###begin p 216
###xml 105 107 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 155 176 154 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
(C) Triglyceride biosynthesis after 24 h incubation with AcLDL (50 mug/ml) measured as incorporation of [14C]oleic acid into triglycerides as described in Materials and Methods.
###end p 216
###begin p 217
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
(D) Uptake of AcLDL was calculated as a sum of 125I-AcLDL specifically taken up and degraded by cells.
###end p 217
###begin p 218
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 115 136 115 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(E) Phospholipid biosynthesis measured as incorporation of [14C]choline into phospholipid fraction as described in Materials and Methods; an asterisk (*) indicates p < 0.01.
###end p 218
###begin title 219
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 78 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Identification of HIV-1-Positive Macrophages in Atherosclerotic Plaques of HIV-Infected Subjects.
###end title 219
###begin p 220
Single (A-D) and double (E and F) immunostaining of aortic wall segments.
###end p 220
###begin p 221
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) p24 staining. A low-magnification image showing the presence of p24+ cells in an area adjacent to the plaque lipid core. The scale bar represents 100 mum.
###end p 221
###begin p 222
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(B) Detail of (A). p24+ cells show a characteristic morphology of foam cells. The scale bar represents 10 mum.
###end p 222
###begin p 223
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(C) CD68 staining. CD68+ cells were identified in a parallel consecutive section to that shown in (A). The scale bar represents 100 mum.
###end p 223
###begin p 224
(D) Negative control (staining with an irrelevant primary antibody). The scale bar represents 100 mum.
###end p 224
###begin p 225
###xml 130 136 <span type="species:ncbi:9986">rabbit</span>
###xml 267 272 <span type="species:ncbi:10090">mouse</span>
(E) Double immunostaining showing the co-localization of p24 (brown) with CD68 (rose). Immunostaining included a combination of a rabbit polyclonal anti-p24 antibody in the peroxidase-anti-peroxidase system with DAB chromogen yielding a brown reaction product, and a mouse monoclonal antibody to CD68 in the alkaline phosphatase-anti-alkaline phosphatase system with Fast Red chromogen, resulting in a rose precipitate. Counterstaining was with Mayer's hematoxylin. The scale bar represents 50 mum.
###end p 225
###begin p 226
(F) A detail of (E). The scale bar represents 15 mum.
###end p 226
###begin title 227
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cholesterol Efflux and Infectivity of HIV Virions
###end title 227
###begin p 228
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human monocyte-derived macrophages were infected with HIV-1 ADA or mock-infected, and 7 d after infection were treated or not treated with LXR agonist, TO-901317 (500 nM), for seven more days.
###end p 228
###begin p 229
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 207 210 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Cholesterol efflux to apoA-I was measured on day 21 after infection. An asterisk (*) indicates p < 0.01 (versus uninfected cells not treated with TO-901317); a number sign (#) indicates p < 0.01 (versus HIV-infected cells not treated with TO-901317).
###end p 229
###begin p 230
###xml 405 406 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(B) Virions were collected from culture supernatants of LXR agonist-treated and untreated (control) cells on day 10 and day 14 (pooled together), adjusted according to p24 content, and analyzed for infectivity on indicator P4-CCR5 cells. Experiment was performed in triplicate, and results (mean +/- SD) are presented as percent infectivity of virions produced by control cells; an asterisk (*) indicates p < 0.001.
###end p 230
###begin p 231
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 272 273 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C) Incorporation of [3H]cholesterol into virions produced by LXR agonist-treated and untreated (control) cells was measured in triplicate, and results (mean +/- SD) are presented relative to cholesterol in the virions produced by control cells; an asterisk (*) indicates p < 0.001.
###end p 231
###begin p 232
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 232
###begin p 233
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. AD, YVB, MB, and DS conceived and designed the experiments. ZM, HR, MPM, TP, LD, NM, YF, JMO, and YVB performed the experiments. ZM, MPM, TP, AD, JMO, YVB, MB, and DS analyzed the data. MB and DS wrote the paper.
###end p 233
###begin p 234
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported in part by the National Institutes of Health (NIH) grants R03 TW006238 and R21 DK072926 (MB and DS), a grant from the Campbell Foundation (MB), grants from the American Heart Association (MB and ZM), and grants #317810 and #317811 from the National Health and Medical Research Council of Australia (DS) and Australian Postgraduate Award #1549 (HR).
###end p 234

